NPR, Inter Press Service examine efforts to prevent drug-resistant malaria

NewsGuard 100/100 Score

As part of its continuing coverage of malaria, NPR's "Shots" blog features a story on counterfeit anti-malarial drugs, which "are among the most popular drugs to fake." According to the blog, "[T]hese faux pharmaceuticals are particularly dangerous because malaria can kill a person in a matter of days," and, if the drugs contain only a small amount of the real drug, they can contribute to the development of drug-resistant malaria parasites. "And that appears to be happening now in Southeast Asia with one of the most powerful anti-malarials, artemisinin," the blog writes (Beaubien, 12/19).

In related news, Inter Press Service examines efforts to track and treat drug-resistant malaria along the Thai-Myanmar border. Fatoumata Nafo-Traore, head of the Roll Back Malaria Partnership, said, "We need to contain the resistance in these local areas. ... This has to be seen as a global concern because there is no other highly effective anti-malaria drug than artemisinin therapy," according to the news service. IPS highlights the need for sustained funding to contain the spread of drug-resistant malaria in the region (Macan-Markar, 12/20).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative approaches needed to overcome health system barriers in malaria vaccination